comparemela.com

Latest Breaking News On - இருதய தலையீடு - Page 1 : comparemela.com

Idorsia Pharmaceuticals Ltd: Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

Idorsia Pharmaceuticals Ltd: Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland - June 2 , 2021 Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study SOS-AMI to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia s P2Y 12 receptor antagonist, in suspected acute myocardial infarction (AMI). An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle (myocardium) is suddenly decreased or completely cut off by a blood clot in one or more of the coronary vessels. An AMI requires immediate treatment, as any delay in intervention can result in irreversible damage to the heart muscle and adverse clinical outcomes. According to the US Centers for Disease Control and Prevention, each year more than 80

Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute . Idorsia Pharmaceuticals LtdJune 28, 2021 GMT   Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland – June 28, 2021 Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI). An AMI, or heart attack, is a life-threatening condition that occurs when blood flow to the heart muscle (myocardium) is suddenly decreased or completely cut off by a blood clot in one or more of the coronary vessels. An AMI requires immediate treatment, as any delay in intervention can result in irreversi

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.